Logo.jpg
ProPhase Labs’ Linebacker-1 Cancer Therapeutic shows promising mechanisms of action as both a mono-therapy and co-therapy in preclinical studies attacking a range of hard-to-treat cancers, including lung and gastric cancers
May 03, 2023 08:30 ET | ProPhase Labs, Inc.
Garden City, NY, May 03, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, today provided an update regarding its...
Picture1
ProPhase Labs CEO Ted Karkus Named One of Inc Magazine’s 10 Most Innovative Healthcare Leaders to Watch in 2023
April 28, 2023 08:30 ET | ProPhase Labs, Inc.
Garden City, NY, April 28, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, is pleased to announce that Ted...
Logo.jpg
ProPhase Labs Announces Launch of Redesigned Corporate Website
April 25, 2023 08:30 ET | ProPhase Labs, Inc.
Garden City, NY, April 25, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, today announced the launch of its...
Logo.jpg
ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 & 1x1 Meetings on Thursday, April 27, 2023
April 18, 2023 08:00 ET | ProPhase Labs, Inc.
GARDEN CITY, NY, April 18, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified biotech, genomics and diagnostics company, today announced that it will be...
Logo.jpg
ProPhase Labs Announces Record Financial Results for the year ended December 31, 2022
March 28, 2023 08:00 ET | ProPhase Labs, Inc.
Company highlights key strategic initiatives to grow underlying value in 2023 and beyond Company announces it is in strategic discussions to develop BE-Smart cancer test globally Company to hold a...
Logo.jpg
ProPhase Labs to Host 2022 Year End Financial Results Conference Call on Tuesday, March 28, 2023 at 11:00 a.m. Eastern Time
March 21, 2023 08:00 ET | ProPhase Labs, Inc.
GARDEN CITY, NY, March 21, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, will hold a conference call on...
Logo.jpg
ProPhase Labs Announces New $6 Million Stock Repurchase Program
March 15, 2023 08:00 ET | ProPhase Labs, Inc.
Garden City, NY, March 15, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its Board of...
Logo.jpg
ProPhase Labs’ Nebula Genomics Subsidiary Introduces Lowest Ever NGS Pricing of $249 for its Whole Genome Sequencing DNA Test
March 07, 2023 08:00 ET | ProPhase Labs, Inc.
Company Provides Update on Significant Progress at Nebula Genomics Subsidiary Garden City, NY, March 07, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented...
Logo.jpg
ProPhase Labs Announces Collaboration with mProbe, Inc. and Mayo Clinic for the Continuing Development of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test
March 01, 2023 08:00 ET | ProPhase Labs, Inc.
Company Outlines BE-Smart Test Roadmap for Commercialization in the U.S. Company in Early Stages of Exploring Development for Commercialization in Other Countries Garden City, NY, March 01,...
Logo.jpg
ProPhase Labs Announces Plans to Initiate Clinical Trial of Equivir (OTC)
February 22, 2023 08:00 ET | ProPhase Labs, Inc.
Goal to launch commercially in Q4 2023 Garden City, NY, Feb. 22, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics...